Mohammad Abdollahi (MA) acquired a PharmD in 1988 from the University of Tehran and then finished a PhD in Toxicology and Pharmacology in 1994 from the Tehran University of Medical Sciences (TUMS). He gained a postdoctoral training in Mechanistic and Clinical Toxicopharmacology at the University of Toronto in 2001. MA has obtained the honor of full professorship of TUMS since the second half of 2002. Since 1997, he contributed in the establishment of Tehran Drug and Poison Information Center for 8 years. MA chaired the Department of Toxicology & Pharmacology since the second half of 2005 until mid of 2016. Also MA has been the Director of National Board of Toxicology for 9 years and Chair of National Society of Toxicology for 8 years. MA has been involved in establishment of Pharmaceutical Sciences Research Center (PSRC) of TUMS as a Cofounder Vice-Chair, and Manager of Ethics Board since 2003; From the August of 2016 he chairs the PSRC. He chaired the Central Library of TUMS between 2004 and 2006. During 2014-2016, MA established and chaired the Drug Discovery and Evaluation Department at the National Institute of Medical Research Development. He was the Vice-Chair for International Affairs of the Faculty of Pharmacy, TUMS between 2015 and 2016. Between mid 2015 and mid 2017, MA directed the Secretariat of the Council of Pharmaceutical Sciences Education and did an excellent job in reforming the Pharmacy education curriculum. In 2013, MA founded a Knowledge-Based Company to uncover the critical mechanistic connections between the toxicity of chemicals and the etiology of human diseases and the introduction of new medicines to protect humans and the environment. Since February 2018, MA chairs The Institute of Pharmaceutical Sciences.
So far, MA has contributed in authoring more than 900 papers in prestigious journals and authoring more than 50 book chapters and editing 12 books. MA has been listed among top scientists of ESI/ISI and OIC Member States. According to GS, current H-index, total citations, and i10 index of MA are 78, >24500, and 470, respectively. Since 2004, MA received recognition by the ESI as one of the top 1% scientists concurrently in the fields of "Pharmacology and Toxicology" and "Clinical Medicine". Besides having the position of DARU Editor-in-Chief (EiC) a journal of TUMS published by BMC followed up by Springer Nature series since 2012, MA has been a member of the BMC Editors Advisory Group in UK started from 2013. MA was one of the Founders and the EiC to another journal titled “Journal of Medical Hypotheses & Ideas” published by the Elsevier (Netherlands). He has also served on the editorial board of many other journals and is an individual member of many academic societies such as EUROTOX and SOT of USA (full member). MA has cooperated with some key international organizations such as the OPCW (Organization for Prohibition of Chemical Weapons) as a member of Scientific Advisory Board in the Netherlands (since 2012), WHO (World Health Organization) as a Member of Guideline Developing Group for Prevention of Lead Poisoning in Switzerland (since 2011), COPE (Committee on Publication Ethics) as a Council Member in the UK (2013-2017) , IAS (Islamic-World Academy of Sciences) as a Fellow (since 2007), and International Society of Pharmacoeconomics and Outcomes Research (ISPOR) Iran Chapter as a Co-Founder and Board of Directors (since 2013). In addition to more than 15 prestigious national awards, MA has received the prominent award of IAS-COMSTECH in 2005 in the field of Pharmacology & Toxicology. The main research interests of MA are Mechanistic and Environmental Toxicology, Evidence-Based Medicine, and Pharmacology. MA’s contributions to this field is attested by an extensive array of citations in papers and books. MA has uncovered the critical mechanistic connections between the toxicity of chemicals and the etiology of human diseases.